Zachary Bessette

Zachary Bessette

Articles by Zachary Bessette

Zachary BessettemHSPC | January 31, 2023
Dr. Deek shares what research should be done to better personalize care for patients with oligometastatic prostate cancer.
View More
Zachary BessettemHSPC | January 31, 2023
Dr. Deek shares what “high-risk mutation” signified in his study and how patients with “high-risk mutation” should be ...
Zachary BessetteNext-Generation Imaging | January 31, 2023
Dr. Deek shares how PSMA imaging used in both the STOMP and ORIOLE trials.
Zachary BessettemHSPC | January 31, 2023
Dr. Deek shares how he evaluated long-term outcomes of MDT in om CSPC in both the ORIOLE and STOMP trials.
Joshua Meeks, MD, PhDNon-Muscle Invasive Urothelial Carcinoma | January 27, 2023
Joshua Meeks, MD, PhD, discusses ongoing research in NMIBC and the future of urothelial carcinoma care.
Zachary BessetteUpper Tract Urothelial Carcinoma | January 25, 2023
Intracorporeal DUBC may be a safe and effective alternative to RNU for UTUC, according to a new research.
Zachary BessetteNext-Generation Imaging | January 24, 2023
Dr. Ulaner highlights the line(s) of therapy in which novel RLT-PSMA agents are being developed.
Zachary BessetteNext-Generation Imaging | January 24, 2023
Dr. Ulaner explains the data that led to the FDA approval of 177Lu-PSMA-617 and the safety profile of this drug.
Zachary BessetteNext-Generation Imaging | January 24, 2023
Dr. Ulaner details the current application and capabilities of molecular imaging in prostate cancer.
Moffitt Cancer Center developed the first PRO measure for patients receiving RNT to guide treatment and improve QoC.